Cardiology - Global Cardiology Academy

1-16 of 334

CME/CE In-Person Event
Moving the Needle in oHCM: The Era of Cardiac Myosin Inhibitors
August 29, 2026
Munich
0.75 credits
CME/CE In-Person Event
Engineering Safer Antithrombotic Strategies for Secondary Stroke Prevention
August 29, 2026
Munich
0.75 credits
CME/CE In-Person Event
Translating Evidence Into Practice: Myosin Inhibition Across the HCM Spectrum
August 30, 2026
Munich
0.75 credits
CME/CE In-Person & Virtual Event
Unmasking HCM in Patients With Preserved EF: Diagnostic Clarity, Evolving Evidence, and Emerging Therapeutic Strategies
October 10, 2026
Multiple locations available
1.00 credit
The Long Road to an FCS Diagnosis
The Long Road to an FCS Diagnosis
On the Frontlines of Familial Chylomicronemia Syndrome
The Long Road to an FCS Diagnosis
Charles Turck, PharmD, BCPS, BCCCP; Peter P. Toth, MD, PhD, FAAFP, FICA, FAHA, FNLA, FCCP, FACC
- Charles Turck, PharmD, BCPS, BCCCP
- Peter P. Toth, MD, PhD, FAAFP, FICA, FAHA, FNLA, FCCP, FACC
Could It Be FCS? Recognizing the Diagnostic Clues
Could It Be FCS? Recognizing the Diagnostic Clues
On the Frontlines of Familial Chylomicronemia Syndrome
Could It Be FCS? Recognizing the Diagnostic Clues
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA; Zahid Ahmad, MD, FNLA
- Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
- Zahid Ahmad, MD, FNLA
Evaluating ASCVD Risk with the CPR Framework
Evaluating ASCVD Risk with the CPR Framework
Heart Matters
Evaluating ASCVD Risk with the CPR Framework
Roger Blumenthal, MD
- Roger Blumenthal, MD
Familial Chylomicronemia Syndrome: Improving Recognition and Diagnosis
Familial Chylomicronemia Syndrome: Improving Recognition and Diagnosis
On the Frontlines of Familial Chylomicronemia Syndrome
Familial Chylomicronemia Syndrome: Improving Recognition and Diagnosis
Steve Jackson, PharmD; Nivedita Patni, MD
- Steve Jackson, PharmD
- Nivedita Patni, MD
Macitentan in Pediatric PAH: Results from the TOMORROW Trial
Macitentan in Pediatric PAH: Results from the TOMORROW Trial
Clinician's Roundtable
Macitentan in Pediatric PAH: Results from the TOMORROW Trial
No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
CME/CE
No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
Brendon Neuen, MBBS, PhD; Katherine Tuttle, MD
0.25 credits
- Brendon Neuen, MBBS, PhD
- Katherine Tuttle, MD
0.25 credits
AI in Pulmonary Hypertension Demonstrates Progress—with Caveats
AI in Pulmonary Hypertension Demonstrates Progress—with Caveats
Clinician's Roundtable
AI in Pulmonary Hypertension Demonstrates Progress—with Caveats
Multi-Omics Brings New Clarity to the REHAB-PH Trial
Multi-Omics Brings New Clarity to the REHAB-PH Trial
Clinician's Roundtable
Multi-Omics Brings New Clarity to the REHAB-PH Trial
Targeting the Hippo Pathway in Pulmonary Arterial Hypertension
Targeting the Hippo Pathway in Pulmonary Arterial Hypertension
AudioAbstracts
Targeting the Hippo Pathway in Pulmonary Arterial Hypertension
Ryan Quigley
- Ryan Quigley
Hypertension in Women: Cardiovascular Risk Across the Lifespan
Hypertension in Women: Cardiovascular Risk Across the Lifespan
Heart Matters
Hypertension in Women: Cardiovascular Risk Across the Lifespan
Shelina Ramnarine, PhD; Payal Kohli, MD, FACC
- Shelina Ramnarine, PhD
- Payal Kohli, MD, FACC
How Symptoms Shape Caregiver Burden in ATTR-CM
How Symptoms Shape Caregiver Burden in ATTR-CM
AudioAbstracts
How Symptoms Shape Caregiver Burden in ATTR-CM
Ryan Quigley
- Ryan Quigley
Exploring Deeper Silencing in Transthyretin Amyloidosis
Exploring Deeper Silencing in Transthyretin Amyloidosis
AudioAbstracts
Exploring Deeper Silencing in Transthyretin Amyloidosis
Ryan Quigley
- Ryan Quigley

Prev
1
2
3
…
20
21
Next

1/6